The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts

Drug Safety

Volumn 19, Issue 1, 1998, Pages 1-10

  Olsson, Sten ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; INFORMATION SERVICE; INTERNATIONAL COOPERATION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG MONITORING; HUMANS; INFORMATION SERVICES; INTERNATIONAL COOPERATION; WORLD HEALTH ORGANIZATION;

EID: 0031903233     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819010-00001     Document Type: Article

References (30)

1. Edwards IR, Fucik H. Impact and credibility of the WHO adverse reaction signals. Drug Inf J 1996; 30: 461-4
2. Olsson S, Biriell C, Boman G. Photosensitivity during treatment with azapropazone. BMJ 1985: 291: 939
3. Stricker BHCh, Meyboom RHB, Lindquist M. Acute hypersensitivity reactions to paracetamol. BMJ 1985; 291: 938-9
4. Stricker BHCh, van Dijke CPH, Isaacs AJ, et al. Skin reactions to terfenadine. BMJ 1986; 293: 536
5. Stricker BHCh, Biriell C. Skin reactions and fever with indapamide. BMJ 1987; 295: 1313-4
6. Stricker BHCh. Slagboom G. Demeaseneer R, et al. Anaphylactic reactions to cinoxacin. BMJ 1988; 297: 1434-5
7. Biriell C, McEwen J, Sanz E. Depression associated with diltiazem [letter]. BMJ 1989; 299: 796
8. Li D, Lindquist M, Edwards IR. Evaluation of early signals of drug-induced Stevens-Johnson Syndrome in the WHO ADR data base. Pharmacoepidemiol Drug Saf 1992; 1: 11-8
9. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992; 305: 451-2
10. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748-9
11. Meyboom RHB, Olsson S, Knol A, et al. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiol Drug Saf 1994; 3: 185-9
12. Fraunfelder FT, Edwards IR. Possible ocular adverse effects associated with leuprolide injections. JAMA 1995; 273 (10): 773-4
13. Meyboom RHB, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines [letter]. Lancet 1995; 345: 1638
14. Alder J, Fraunfelder FT, Edwards IR. Levonorgestrel implants and intracranial hypertension. N Engl J Med 1995; 332 (25): 1720-1
15. Lindquist M, Edwards IR. Risks of non-sedating antihistamines [letter]. Lancet 1997; 349: 1322
16. US Department of Health and Human Services. Health Advisory on Fenfluramine/Phentermine for Obesity. HHS News 1997 Jul 8
17. Edwards IR. Adverse Drug Reactions: Finding the needle in the haystack [editorial]. BMJ 1997; 315: 500
18. Finney DJ. Systematic signalling of adverse reactions to drugs. Meth Inform Med 1974; 13: 1-10
19. Lindquist M, Sanderson J, Claesson C, et al. New pharmacovigilance information on an old drug - an international study of spontaneous reports on digoxin. Drug Invest 1994; 8 (2): 73-80
20. Lindquist M, Pettersson M, Edwards IR, et al. Omeprazole and visual disorders: seeing alternatives. Pharmacoepidemiol Drug Saf 1996; 5: 27-32
21. Lindquist M, Pettersson M, Edwards IR, et al. How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacol Toxicol 1997; 80: 211-7
22. Lindquist M, Pettersson M, Edwards IR, et al. Withdrawal reactions with selective serotonin reuptake inhibitors (SSRIs) as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9
23. McNamee D. Speaking about pharmacovigilance [editorial]. Lancet 1996; 348: 908
24. Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997; 17 (4): 216-27
25. Olsson S, editor. National pharmacovigilance systems-country profiles and overview. Uppsala: The Uppsala Monitoring Centre, 1997
26. Nainggolan L. Heart valve problems first seen with obesity drugs in 1994/5. Scrip 1997; No 2294: 20
27. Bate A, Lindquist M, Edwards IR, et.al. A Bayesian neural network method for adverse drug reaction signal detection. Eur J Clin Pharmacol. In press
28. McNamee D. Communicating drug safety information. Lancet 1997; 350: 1646
29. The Erice Declaration on Communicating Drug Safety Information, HAInews 1997; No 98: 9
30. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102